Delivering Cutting-Edge Technology

TSO3 is Positioned for Success Today and in the Future.

TSO3 is a commercialization-stage medical device company providing cutting-edge low temperature terminal sterilization technology that offers an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals and ambulatory surgical facilities. TSO3’s flagship product is the STERIZONE® VP4 Sterilizer – a low-temperature sterilization system that utilizes the dual sterilants of vaporized hydrogen peroxide (H2O2) and ozone (O3) to achieve terminal sterilization of heat and moisture sensitive medical devices. The STERIZONE® VP4 Sterilizer is the only Food and Drug Administration (FDA) cleared low temperature sterilizer that can process large 75 lb mixed instrument loads and is also the only terminal sterilization method that is FDA cleared to sterilize certain multi-channeled flexible endoscopes, such as colonoscopes, duodenoscopes and gastroscopes.

TSO3’s global market opportunity includes the traditional low temperature sterilization applications in the $6 billion sterilization industry in over 25,000 hospitals, as well as a burgeoning unique opportunity to terminally sterilize over 50 million annual colonoscopies, gastroscopies and other endoscopic procedures.

Our business model includes the sale of the sterilizer, as well as recurring revenue from the sale of consumables and services. With a rapidly evolving healthcare industry that is mandating the sterilization of more devices, and outstanding customer reviews from our existing and growing user base, TSO3 is poised to significantly disrupt the existing large and well defined global market with innovative sterilization technologies that provide safe care for patients, and save money and increase efficiency for healthcare facilities.

Latest News and Events

Stay up to date on important investor news and information.

Meet our team.

Get to know the management team and board of directors.

Analyst Coverage

Neil MaruokaCanaccord Genuity416.869.3073
Frédéric TremblayDesjardins Capital Markets514.841.0283
Douglas W. LoeEchelon Wealth Partners Inc.416.775.1004
Nick AgostinoLaurentian Bank Securities, Inc.416.865.5967
Endri LenoNational Bank Financial416.869.8047
Douglas MiehmRBC Capital Markets416.842.7823

Any opinions, estimates or forecasts regarding TSO3‘s performance made by analysts are theirs alone and do not represent the opinions, forecasts or predictions of TSO3 Inc. or its management. TSO3 does not, by its reference on this website, imply its endorsement of, or concurrence with, information, conclusions or recommendations made by analysts.

Investor Relations

Greg Chodaczek
Gilmartin Group LLC
Tel.: 610-368-6505
E-mail: greg@gilmartinIR.com

www.gilmartinIR.com

Barry Mire
Renmark Financial Communications Inc.
Tel.: 416 644-2020 or 514 939-3989
Fax: 416 644-2021
E-mail: bmire@renmarkfinancial.com

www.renmarkfinancial.com